FDA approval of an generic intravenous edaravone formulation; represents regulatory authorization but does not report clinical trial outcomes or comparative efficacy data.
Reported
Approval date2026-07-22
FormulationSOLUTION, INTRAVENOUS, 30MG/100ML (0.3MG/ML)
Application typeORIG (original application)